Vigil Neuroscience

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Our mission is to provide state-of-the-art neuropsychological services to people of all backgrounds and abilities, with the aim of improving their overall mental health, mental well-being, and resiliency.

Our vision is to develop a transformative neuropsychological treatment technology that increases access to care and improves mental health outcomes in all communities.

So far, Vigil Neuroscience has been acknowledged by the American Psychological Association, the American Psychiatric Association, and other key stakeholders as a leader in neuropsychology services and innovation.